CA224123] A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristoll Myers Squibb
Start Date
August 31, 2022
End Date
February 26, 2027
Administered By
Duke Cancer Institute
Awarded By
Bristoll Myers Squibb
Start Date
August 31, 2022
End Date
February 26, 2027